SUPN – supernus pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 21 Filed by: NEWHALL CHARLES W III
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 13 Filed by: Bhatt Padmanabh P.
Form SCHEDULE 13G/A SUPERNUS PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30
Form 8-K SUPERNUS PHARMACEUTICALS For: Nov 04
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.